drugset / Trial / NCT03936829

Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes

NCT03936829

Active not recruiting 10 enrolled Children's Hospital of Fudan University
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the change of insulin resistance and glucose metabolism of patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the treatment of cyclophosphamide.

Timeline

Start
2019-04-28
Primary completion
2028-05-31
Completion
2030-05-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous